Gabapentin is a gamma-aminobutyric acid derivative, and was approved for the treatment of neuropathic pain by the U.S. Food and Drug Administration in 2002. However, little evidence is available on the effects and me-chanisms of action of gabapentin during the migraine attack period. A recent study by Yanbo Zhang and colleague from Xuanwu Hospital, Capital Medical University in China showed that excitatory amino acids and protein kinase C are involved in the formation and maintenance of central sensitization during migraine. Gabapentin can decrease neuronal excitability in spinal trigeminal nuclei and inhibit the formation of central sensitization during migraine by reducing excitatory amino acid content in the cerebrospinal fluid and by inhibiting protein kinase C activation. These findings were published in the Neural Regeneration Research (Vol. 8, No. 32, 2013).
|Contact: Meng Zhao|
Neural Regeneration Research